Evidence map›Paper›PMID 41685251›Full record

ArticleFrontiers in endocrinology2026

Baicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway.

Nan Wu, Yang Wu, Qian Zhang, Muhammad Naeem, Ren Jing, Yuan-Bin Luo, Shijian Yi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nan WuDepartment of Breast and Thyroid Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Yang WuDepartment of Breast and Thyroid Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Qian ZhangRespiratory Medicine, Shenzhen Pingle Orthopedic Hospital, Shenzhen, China.
Muhammad NaeemDepartment of Breast and Thyroid Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Ren JingDepartment of Breast and Thyroid Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Yuan-Bin LuoDepartment of Breast and Thyroid Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Shijian YiDepartment of Breast and Thyroid Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Papillary thyroid cancer (PTC) is the most common type of endocrine malignancy caused by genetic mutations, hormonal imbalances, and environmental factors. However, recurrent infections, and metastasis in PTC patients remain challenged due to complexity of traditional methods. Baicalein (BA) is a kind of natural flavonoid that exhibits the anti-cancer, anti-inflammatory, anti-tumor, and anti-viral activities. The molecular mechanism of baicalein in pathogenesis of PTC remains unclear. This study was designed to explore the inhibitory effects of BA against PTC by mediating the Golgi apparatus reprogramming via PLAU and suppressing the TPL2/MEK2/ERK2 pathway. Methods: Transcriptomic analysis was performed to explore the gene expression profiles. Molecular docking was employed to identify the potential targets to elucidate the molecular mechanism of action of BA. Results: PLAU, an up-regulated DEG, is implicated in tumor development, lymph node metastasis, and infiltration levels of neutrophils and dendritic cells in thyroid cancer patients. Molecular docking analysis revealed that serum levels of uPA protein encoded by PLAU and Conclusion: It was concluded it could be served as a promising therapeutic strategy for the treatment of PTC.

Indexed as

FlavanonesMAP Kinase Kinase 2MAP Kinase Kinase KinasesMAP Kinase Signaling SystemMitogen-Activated Protein Kinase 1Proto-Oncogene ProteinsThyroid Cancer, PapillaryThyroid NeoplasmsAnimalsCell Line, TumorCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansMiceMolecular Docking SimulationbaicaleinFlavanonesMAP3K8 protein, humanMAPK1 protein, humanMAP Kinase Kinase 2MAP Kinase Kinase KinasesMitogen-Activated Protein Kinase 1Proto-Oncogene ProteinsbaicaleinGolgi apparatusMAPK pathwayPLAUPTCthyroid cancer

Identifiers

PMID41685251
PMCPMC12890616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.